Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
In accordance with the terms previously announced, Atrium Innovations Inc. announced that it has completed the sale of its Active Ingredients and Specialty chemicals division for total proceeds of US$166.4 million in cash, subject to a post-closing working capital adjustment. Atrium is now a health and nutrition pure-play and the net proceeds from the transaction shall provide the Company with better financial flexibility to pursue its corporate strategy.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.